$ACOG

Opaleye Management Inc. purchased $59K of ACOG (indirect holdings)

Opaleye Management Inc. purchased 10,054 indirectly-held shares of Alpha Cognition Inc. (ACOG) at $5.83 on 2026-06-05.

Original reporting
SEC EDGAR · Opaleye Management Inc.
Published Jun 9, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 9, 2026, 8:10 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ACOG
Bullish
medium confidence
Mentioned
$ACOG
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ACOGBullishLow
01

Why it matters

Traders may treat the disclosure as a minor positive sentiment datapoint, but it does not provide new operational or financial fundamentals.

02

Market read

New insider accumulation fact disclosed via SEC EDGAR; likely low incremental trading impact absent follow-on activity.

03

What to watch

No 10b5-1 plan is cited; without context on prior trading cadence or total ownership changes, the signal strength is uncertain.

Relevance 4/10Novelty 8/10Timing: Form 4 filed June 9 (transaction dated June 5)

Background

The filing is an SEC Form 4 insider transaction: Opaleye Management Inc. reported an open-market purchase in Alpha Cognition Inc. stock.

Company-level read

Ticker impact

$ACOGBullishMedium confidence
Context

Opaleye Management Inc. (a 10% owner) bought 10,054 shares of Alpha Cognition Inc. for ~$58.6K via an open-market Form 4 filed June 9.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and should fade unless followed by larger buys or fundamental catalysts.

Evidence & confidence

The article is a primary SEC Form 4 disclosure (new fact), but the transaction size (~$59K) is relatively small, and there is no 10b5-1 plan disclosed.

Market effects

No sector-level implications; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

A small open-market buy by a 10% owner may reflect routine portfolio management rather than a strong forward-looking view.

Key entities

  • Alpha Cognition Inc.

    Subject of the Form 4 insider transaction; shares purchased by a 10% owner.

  • Opaleye Management Inc.

    10% owner reporting an open-market purchase of ACOG shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ACOGMed

Alpha Cognition Q2 Earnings Call Highlights

Alpha Cognition (NASDAQ:ACOG) said ZUNVEYL demand rose each month in Q2, with June the strongest month to date, and management attributed growth to demand rather than wholesaler or pharmacy stocking. Payer formulary activation lagged expectations, with payer access the key near-term friction. The company reported BEACON study positive top-line results, lowered 2026 operating expense guidance to $50M-$54M, and had $41.4M cash as of June 30.

$ACOGHighAI 9/10

Why is Alpha Cognition stock surging today?

Alpha Cognition (ACOG) shares rose about 12.1% pre-open after its Q2 2026 earnings call. ZUNVEYL net product revenue was about $6.0M, up 71% sequentially and from $1.7M in Q2 2025. Net loss narrowed to $8.8M ($0.40/share). Gross product margin was ~94%, and full-year 2026 operating expense guidance was cut to $50M-$54M; profitability target remains 2027.

$ACOGMed

Alpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer’s Disease

Alpha Cognition Inc. (NASDAQ: ACOG) said the European Patent Office granted a European patent covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for use in treating mild-to-moderate Alzheimer’s disease. The patent covers specific solid form, compositions, manufacturing and medical-use claims, with potential protection into 2042, subject to requirements.